...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Sunitinib-induced Thyrotoxicosis - A not so Rare Entity
【24h】

Sunitinib-induced Thyrotoxicosis - A not so Rare Entity

机译：舒尼替尼诱导的甲状腺毒症-并非如此罕见

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: The tyrosine kinase inhibitor (TKI) sunitinib malate is nowadays a standard first-line treatment option for Patients with metastatic clear-cell renal cell carcinoma (mRCC). The aim of this study was to evaluate the incidence and clinical course of thyrotoxicosis in our cohort of patients treated with sunitinib. Patients and Methods: Medical records of all patients treated with first-line sunitinib for mRCC at our Institution between November 2008 and March 2014 were retrospectively reviewed. Thyroid function was assessed after every 2 cycles of therapy, during the 2 weeks off period. Results: Out of the 62 included patients, hypothyroidism has developed during therapy in 12 patients (19%) and it was preceded by thyrotoxicosis in 2 (3.2%). Conclusion: Sunitinib-induced thyrotoxicosis (SIT), a not so rare entity, was followed by hypothyroidism. The patterns of occurrence and possible significance of SIT, as predictive marker of better treatment response to sunitinib, need to be validated in further studies.
机译：背景/目的：酪氨酸激酶抑制剂（TKI）苹果酸舒尼替尼目前是转移性透明细胞肾细胞癌（mRCC）患者的标准一线治疗选择。这项研究的目的是评估在我们舒尼替尼治疗的患者队列中甲状腺毒症的发生率和临床病程。患者与方法：回顾性分析了我们机构在2008年11月至2014年3月间接受舒尼替尼一线治疗mRCC的所有患者的病历。在休假2周期间，每2个疗程后评估一次甲状腺功能。结果：在62名患者中，有12名患者在甲状腺功能减退症中发展（19％），其次是甲状腺毒症2名（3.2％）。结论：舒尼替尼诱发的甲状腺毒症（SIT）并非罕见，随后是甲状腺功能减退症。作为更好的舒尼替尼治疗反应的预测指标，SIT的发生模式和可能的意义有待进一步研究验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号